HK Stock Market Move | QYUNS-B(02509) rose more than 5% as three long-acting dual anti-resistant drugs successfully entered the overseas market. Institutions are optimistic about the company's leading position in the field of self-immunity.

QYUNS-B (02509) rose more than 5%, as of the time of writing, it was up 5% to HK$18.9, with a turnover of HK$1305.09 million. On the news front, on December 22, Quansheng Biology announced an agreement with a subsidiary of Windward regarding the TSLPxIL-13 dual antibody drug, with a total authorization amount of up to $700 million. It is worth mentioning that this is the third outbound transaction that Quansheng Biology has reached this year. Previously, the company granted global rights to QX030N to Caldera, and authorized QX031N to Roche. China Post Securities pointed out that the company is a leader in domestic self-immunotherapy innovation with good accumulation in this field. The company's mature pipeline is gradually entering a period of realization to enhance hematopoietic capacity, and successive outbound authorizations for innovative pipelines provide further assurance for the company's stable operation. Huachuang Securities indicated that they are optimistic about the company's continued consolidation of its leading position in the field of self-immunotherapy.